Genes (42)
Species: human : 42 | |
Human | MTDH | 92140 | metadherin | AEG-1 is overexpressed in clinical prostate cancer (PC) tissue samples and cultured PC cells compared to benign prostatic hyperplasia tissue samples and normal prostate epithelial cells | Human | AMACR | 23600 | alpha-methylacyl-CoA racemase | expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone | Human | FGF17 | 8822 | fibroblast growth factor 17 | FGF17 expression is increased 2-fold in benign prostatic hyperplasia and may contribute to the increased epithelial proliferation seen in this disease | Human | AKR1C3 | 8644 | aldo-keto reductase family 1, member C3 | Title:Polymorphisms in genes involved in sex hormone metabolism may increase risk of benign prostatic hyperplasia.|Association:Not Found|Conclusion:Polymorphisms in HSD3B1, CYP19, AKR1C3 genes may be associated with an enlarged prostate in older men. These data provide insights into genes that should be examined further for their potential role in the pathogenesis of BPH. (c) 2005 Wiley-Liss, Inc. | Human | VEGFA | 7422 | vascular endothelial growth factor A | VEGF, FGF2, TGFB1, EGF and IGF1 have roles in the development of both prostate cancer and benign prostatic hyperplasia ET-1 from the microvascular endothelium is inhibited by vascular endothelial growth factor and does not have a role as a growth factor in human benign prostatic hyperplasia | Human | VDR | 7421 | vitamin D (1,25- dihydroxyvitamin D3) receptor | Title:Association of vitamin D receptor and 17 hydroxylase gene polymorphisms with benign prostatic hyperplasia and benign prostatic enlargement.|Association:Y|Conclusion:Gene polymorphisms of CYP17 and VDR have no association to prostate volume, clinical parameters, and endocrine parameters in elderly men. The association of CYP17 polymorphism and prostate histology warrants further studies. Assessment of gene polymorphisms might provide new insights into the pathogenesis of benign prostatic hyperplasia and benign prostate enlargement and may hold promise as genetic biomarkers of this disease. VDR TaqI polymorphism is associated with a group of men with benign prostatic hyperplasia who are at an increased risk of prostate cancer | Human | UMPS | 7372 | uridine monophosphate synthetase | thymidylate synthase and orotate phosphoribosyl transferase, but not dihydropyrimidine dehydrogenase, are more highly expressed in prostate cancer than in benign prostatic hyperplasia | Human | TYMS | 7298 | thymidylate synthetase | thymidylate synthase and orotate phosphoribosyl transferase, but not dihydropyrimidine dehydrogenase, are more highly expressed in prostate cancer than in benign prostatic hyperplasia | Human | TGFB1 | 7040 | transforming growth factor, beta 1 | VEGF, FGF2, TGFB1, EGF and IGF1 have roles in the development of both prostate cancer and benign prostatic hyperplasia transforming growth factor-beta 1 gene polymorphism is associated with prostate cancer and benign prostatic hyperplasia | Human | SRD5A2 | 6716 | steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2) | Candidate gene for benign prostatic hyperplasia SRD5A2 gene codes the steroid 5-reductase type II, a critical mediator of androgen action, and the V89L and A49T polymorphisms of this gene may be associated risk of prostate cancer or benign prostatic hyperplasia Title:Impact of constitutional genetic variation in androgen/oestrogen-regulating genes on age-related changes in human prostate.|Association:Not Found|Conclusion:These results suggested that common variants of the CYP17 gene are associated with prostate enlargement and therefore may increase the risk of development of BPH in this population, while infrequent variants of the aromatase gene (CYP19) could be of a protective nature. Polymorphisms within the gene are biomarkers for the development of benign prostatic hyperplasia and benign prostatic enlargement(SRD5A2) Title:A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH.|Association:Not Found|Conclusion:The process(es) in which these silent single-nucleotide polymorphisms (SNPs) influence BPH phenotypes is unknown and additional studies will be needed to assess whether these SNPs have direct functional consequences. The characterization of additional molecular factors that contribute to static and dynamic obstruction may help predict response to pharmacotherapy and serve to identify novel drug targets for the clinical management of BPH. Title:Polymorphisms in the 5alpha reductase type 2 gene and urologic measures of BPH.|Association:Not Found|Conclusion:These findings do not demonstrate consistent associations between SRD5A2 genotypes and BPH. However, they suggest that the associations of V89L polymorphisms and prostate volume should be investigated further. | Human | SRD5A1 | 6715 | steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1) | Title:A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH.|Association:Not Found|Conclusion:The process(es) in which these silent single-nucleotide polymorphisms (SNPs) influence BPH phenotypes is unknown and additional studies will be needed to assess whether these SNPs have direct functional consequences. The characterization of additional molecular factors that contribute to static and dynamic obstruction may help predict response to pharmacotherapy and serve to identify novel drug targets for the clinical management of BPH. | Human | PLAU | 5328 | plasminogen activator, urokinase | uPA mRNA and uPAR mRNA expression were found in 9 and 8 of prostsatic adenocarcinomas, respectively, and in 7 and 6 of benign prostatic hyperplasias | Human | MT3 | 4504 | metallothionein 3 | The goals of this study were to define the expression of the isoforms of MT 1, 2, 3 at both mRNA and protein levels, in normal prostate, benign prostatic hyperplasia (BPH) and malignant PC-3 cells | Human | MAGEA4 | 4103 | melanoma antigen family A, 4 | Present, by immunocytochemistry, in normal prostate, prostatic hypertrophy and prostate cancer | Human | LEPR | 3953 | leptin receptor | Leptin receptor did not reveal a definite difference between benign prostatic hyperplasia and prostate cancer | Human | IGFBP3 | 3486 | insulin-like growth factor binding protein 3 | is inversely associated with benign prostatic hyperplasia risk | Human | IGF1 | 3479 | insulin-like growth factor 1 (somatomedin C) | is positively associated with benign prostatic hyperplasia risk VEGF, FGF2, TGFB1, EGF and IGF1 have roles in the development of both prostate cancer and benign prostatic hyperplasia | Human | HSD3B1 | 3283 | hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 | Title:Polymorphisms in genes involved in sex hormone metabolism may increase risk of benign prostatic hyperplasia.|Association:Not Found|Conclusion:Polymorphisms in HSD3B1, CYP19, AKR1C3 genes may be associated with an enlarged prostate in older men. These data provide insights into genes that should be examined further for their potential role in the pathogenesis of BPH. (c) 2005 Wiley-Liss, Inc. | Human | HLA-G | 3135 | | HLA-G1, -G2, -G5, -G6 mRNAs and proteins in four-to-five samples of normal prostate glands, prostates with benign prostatic hyperplasia and prostate adenocarcinomas using RT-PCR and immunohistochemistry | Human | FGFR4 | 2264 | fibroblast growth factor receptor 4 | FGFR4 Arg allele of the Gly388Arg polymorphism and the G allele of the rs2011077 polymorphism have a significant impact on the development of prostate cancer and benign prostatic hyperplasia | Human | FGF7 | 2252 | fibroblast growth factor 7 | PAR-1 activation strikingly induced FGF-7 production from cultured stromal cells mediated predominantly via ERK1/2 signaling pathway in benign prostatic hyperplasia | Human | FGF2 | 2247 | fibroblast growth factor 2 (basic) | VEGF, FGF2, TGFB1, EGF and IGF1 have roles in the development of both prostate cancer and benign prostatic hyperplasia | Human | FABP5 | 2171 | fatty acid binding protein 5 (psoriasis-associated) | study found levels of nuclear & cytoplasmic C-FABP expression in prostate cancer cells were significantly higher than those in normal & benign prostatic hyperplasia tissues & increased C-FABP was significantly associated with reduced patient survival time | Human | F2R | 2149 | coagulation factor II (thrombin) receptor | The expression and function of PAR-1 in benign prostatic hyperplasia stroma indicate PAR-1 may play important roles in BPH pathogenesis | Human | ERBB2 | 2064 | v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 | Predictive value of a polymorphism in HER-2 (Val655Ile) to determine the risk of developing prostate cancer in patients with benign prostatic hyperplasia |
|